RUTHERFORD, N.J. - Glucotrack, Inc. (NASDAQ:GCTK), a medical device company specializing in diabetes care technology, has ...
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback